Recent preclinical data indicate that luteolin, at doses ranging from 10 to 60 μM, suppresses colon cancer cell proliferation by upregulating Nrf2 and interacting with p53 in a dose-dependent manner [100]. Here, GABPA is linked to colonic neoplasm.